Literature DB >> 7286491

On the stability of immunoreactive glucagon in plasma samples.

T Hendriks, T J Benraad.   

Abstract

The stability of glucagon immunoreactivity in plasma samples, as measured with antiserum 30K, has been investigated. Post-prandial blood samples were collected and processed both with added Trasylol at 4 degrees C and without Trasylol at room temperature. Incubation at room temperature for up to 7h without added Trasylol did not result in significant loss of 30K-immunoreactive glucagon. Blood samples both from non-diabetic and diabetic persons could be collected and centrifuged at room temperature and stored at -20 degrees C without Trasylol for more than 2 months without loss of 30K-immunoreactivity, as compared to Trasylol-containing controls kept at 4 degrees C during handling. The distribution of 30K-immunoreactive glucagon over the various components, obtained after chromatography of plasma on Ultrogel AcA54, was not significantly altered when blood samples, both from normal persons and from patients with chronic renal failure, were processed at room temperature and subsequently stored at -20 degrees C without addition of Trasylol. Our results indicate that collection and centrifugation of blood at room temperature without the addition of a proteinase inhibitor and subsequent storage at -20 degrees C does not result in loss of 30K-immunoreactive glucagon.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286491     DOI: 10.1007/BF00252764

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  7 in total

1.  The destruction of glucagon by the blood plasma from various species.

Authors:  I A MIRSKY; G PERISUTTI; N C DAVIS
Journal:  Endocrinology       Date:  1959-06       Impact factor: 4.736

2.  Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

Authors:  I Valverde; M L Villanueva; I Lozano; J Marco
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

3.  Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasma.

Authors:  J W Ensinck; C Shepard; R J Dudl; R H Williams
Journal:  J Clin Endocrinol Metab       Date:  1972-09       Impact factor: 5.958

4.  A simplified glucagon immunoassay and its use in a study of incubated pancreatic islets.

Authors:  K Nonaka; P P Foà
Journal:  Proc Soc Exp Biol Med       Date:  1969-01

5.  Radioimmunological determination of pancreatic and gut glucagon in plasma.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1971-02       Impact factor: 10.122

6.  A double antibody immunoassay for glucagon.

Authors:  W R Hazzard; P M Crockford; K D Buchanan; J E Vance; R Chen; R H Williams
Journal:  Diabetes       Date:  1968-04       Impact factor: 9.461

7.  Incubation damage in the radioimmunoassay for human plasma glucagon and its prevention with "Trasylol".

Authors:  A M Eisentraut; N Whissen; R H Unger
Journal:  Am J Med Sci       Date:  1968-02       Impact factor: 2.378

  7 in total
  1 in total

1.  Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes.

Authors:  Aris Siafarikas; Robert J Johnston; Max K Bulsara; Peter O'Leary; Timothy W Jones; Elizabeth A Davis
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.